Search

everythinglearnresearchcommunity

for

Search:↓

A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.

IL-15 helps maintain hair growth and protects the immune status of hair follicles.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Tofacitinib may help treat severe hair loss, but more research is needed.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Ruxolitinib can help regrow hair in severe alopecia areata.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Abrocitinib may effectively treat stubborn alopecia universalis.

A patient with complete hair loss regrew all her hair using tofacitinib.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Hair regrows faster in alopecia areata than skin re-pigments in vitiligo due to differences in stem cells and treatment effects.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Abrocitinib may help treat alopecia areata effectively with mild side effects.